Satsuma Stock Is Trading Higher As STS101 Shows Favorable Pharmacokinetic Profile, Tolerability In Early-Stage Study
Satsuma Pharmaceuticals Inc (NASDAQ:STSA) announced positive Pharmacokinetic and safety results from a Phase 1 trial of STS101 (dihydroergotamine (DHE) nasal powder).…